Stockholm, Sweden – June 2024 – Cognes Medical Solutions has been granted a U.S. patent for its AI-powered dementia detection platform, marking a significant step toward revolutionizing early diagnosis and care for neurodegenerative diseases.
The patented solution analyzes facial features using machine learning to identify early signs of cognitive decline. Delivered via a smartphone app, Cognes provides a non-invasive, scalable, and cost-effective screening method that addresses the urgent need for earlier dementia diagnosis.
This U.S. patent follows a European Patent Office (EPO) grant issued in March 2024, expanding Cognes’ international intellectual property portfolio and reinforcing its position at the forefront of digital cognitive health innovation.
What Is Cognes? An AI-Based Dementia Screening App
Cognes is a healthtech platform designed to detect early-stage dementia through AI-driven facial analysis. Users upload photos over time via a smartphone application, and the software monitors subtle facial changes, known as digital biomarkers, that may correlate with cognitive impairment.
This technology enables:
- Early and remote dementia screening
- Objective tracking of cognitive decline
- Improved patient stratification for clinical trials
Unlike traditional diagnostics, which rely on invasive tests, high costs, and delayed access to specialists, Cognes offers an accessible tool that can be used anywhere a smartphone is available.
How Cognes Works: Facial Biomarkers and Machine Learning
Cognes uses proprietary facial recognition algorithms to track micro-expressions and structural changes in facial features over time. These are then correlated with clinical data to detect patterns associated with neurodegenerative conditions such as Alzheimer’s disease.
The software is:
- Non-invasive and user-friendly
- Optimized for repeated, longitudinal monitoring
- Integrated with secure cloud infrastructure for research and clinical use
By enabling more frequent, affordable, and early screenings, Cognes supports timely intervention, better care outcomes, and lower healthcare costs.
Why Early Dementia Detection Matters
Today, up to 75% of dementia cases go undiagnosed until the disease has progressed significantly. This delays care and limits participation in clinical trials aimed at finding better treatments.
Cognes addresses this gap by helping:
- Researchers identify patients earlier for trial recruitment
- Clinicians make informed decisions based on objective data
- Health systems reduce time and cost per diagnosis
With global dementia cases projected to triple by 2050, tools like Cognes are essential for proactive, scalable cognitive care.
A High-Growth HealthTech Investment Opportunity
Cognes is rapidly gaining traction with:
- Two granted patents (U.S. and EPO)
- Partnerships with leading research institutions
- Pilot studies in Europe and North America
The platform offers commercial potential through:
- SaaS licensing to CROs, pharma, and specialist clinics
- Data-driven clinical research applications
- AI-enabled remote patient monitoring
Investors and strategic partners are invited to support Cognes’ mission to transform how the world approaches dementia detection and care.
The Road Ahead: Global Expansion and Research Integration
With patents secured in major markets, Cognes is preparing for large-scale deployment across research, pharma, and healthcare sectors. Its regulatory roadmap includes compliance with GDPR, AI ethics, and future medical device certification.
The company continues to build partnerships across Europe, the U.S., and Asia to expand its database, train its algorithms across diverse populations, and bring early detection into standard practice.
About Cognes Medical Solutions
Cognes Medical Solutions is a Swedish healthtech startup developing AI-powered tools for early detection and monitoring of neurodegenerative diseases. The company’s mission is to make cognitive health screening accessible, scalable, and effective, empowering patients, clinicians, and researchers with actionable insights.